Emodin potentiates the antitumor effects of gemcitabine in PANC-1 pancreatic cancer xenograft model in vivo via inhibition of inhibitors of apoptosis

International Journal of Oncology

Volumn 40, Issue 6, 2012, Pages 1849-1857

  Guo, Hong Chun ^a   Bu, He Qi ^a   Luo, Jiang ^a   Wei, Wei Tian ^d   Liu, Dian Lei ^a   Chen, Hui ^a   Tong, Hong Fei ^a   Wang, Zhao Hong ^a   Wu, Hua Yong ^a   Li, Hong Hai ^a   Zuo, Ming Ming ^a   Li, Wei ^c   Lin, Sheng Zhang ^a,b  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c CAPITAL NORMAL UNIVERSITY   (China)

^d ZHEJIANG CANCER HOSPITAL   (China)

Author keywords

Chemoresistance; Emodin; NF B; Pancreatic cancer; Survivin; XIAP

Indexed keywords

CASPASE 3; CASPASE 9; EMODIN; GEMCITABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KI 67 ANTIGEN; MESSENGER RNA; SURVIVIN; X LINKED INHIBITOR OF APOPTOSIS;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BODY WEIGHT; CANCER CELL DESTRUCTION; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME INDUCTION; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN EXPRESSION; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CASPASES; CELL LINE, TUMOR; DEOXYCYTIDINE; DOWN-REGULATION; DRUG SYNERGISM; EMODIN; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; KI-67 ANTIGEN; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NF-KAPPA B; PANCREATIC NEOPLASMS; TUMOR BURDEN; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84861785810     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1389     Document Type: Article

References (40)

1. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
2. Hidalgo M: Pancreatic cancer. N Engl J Med 362: 1605-1617, 2010.
3. Gudjonsson B: Pancreatic cancer: survival, errors and evidence. Eur J Gastroenterol Hepatol 21: 1379-1382, 2009.
4. Wray CJ, Ahmad SA, Matthews JB and Lowy AM: Surgery for pancreatic cancer: recent controversies and current practice. Gastroenterology 128: 1626-1641, 2005. (Pubitemid 40692556)
5. Lockhart AC, Rothenberg ML and Berlin JD: Treatment for pancreatic cancer: current therapy and continued progress. Gastroenterology 128: 1642-1654, 2005. (Pubitemid 40692557)
6. Oettle H, Post S, Neuhaus P, et al: Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curativeintent resection of pancreatic cancer: a randomized controlled trial. JAMA 297: 267-277, 2007. (Pubitemid 46143304)
7. Wang Z, Li Y, Ahmad A, et al: Pancreatic cancer: understanding and overcoming chemoresistance. Nat Rev Gastroenterol Hepatol 8: 27-33, 2011.
8. Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG and Benson AB III: Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 20: 3270-3275, 2002. (Pubitemid 34831525)
9. Louvet C, Labianca R, Hammel P, et al: Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 23: 3509-3516, 2005.
10. Heinemann V, Quietzsch D, Gieseler F, et al: Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 24: 3946-3952, 2006. (Pubitemid 46630743)
11. Rocha Lima CM, Savarese D, Bruckner H, et al: Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. J Clin Oncol 20: 1182-1191, 2002. (Pubitemid 34177423)
12. Kullmann F, Hollerbach S, Dollinger MM, et al: Cetuximab plus gemcitabine/oxaliplatin (gEMOxCET) in first-line metastatic pancreatic cancer: a multicentre phase II study. Br J Cancer 100: 1032-1036, 2009.
13. Andersson R, Aho U, Nilsson BI, et al: Gemcitabine chemoresistance in pancreatic cancer: molecular mechanisms and potential solutions. Scand J Gastroenterol 44: 782-786, 2009.
14. Hagmann W, Jesnowski R and Lohr JM: Interdependence of gemcitabine treatment, transporter expression, and resistance in human pancreatic carcinoma cells. Neoplasia 12: 740-747, 2010.
15. Liu A, Hu YS, Wang ZH, Tang LL, Ke PY and Lin SZ: Role of nuclear factor-kappaB on emodin-induced sensitization of pancreatic cancer to gemcitabine. Yao Xue Xue Bao 46: 146-152, 2011.
16. Li-Weber M: Targeting apoptosis pathways in cancer by Chinese medicine. Cancer Lett doi: 10.1016/j.canlet.2010.07.015.
17. Li HL, Chen HL, Li H, et al: Regulatory effects of emodin on NF-kappaB activation and inflammatory cytokine expression in RAW 264.7 macrophages. Int J Mol Med 16: 41-47, 2005.
18. Lin SZ, Chen KJ, Tong HF, Jing H, Li H and Zheng SS: Emodin attenuates acute rejection of liver allografts by inhibiting hepatocellular apoptosis and modulating the Th1/Th2 balance in rats. Clin Exp Pharmacol Physiol 37: 790-794, 2010.
19. Liu A, Chen H, Wei W, et al: Antiproliferative and antimetastatic effects of emodin on human pancreatic cancer. Oncol Rep 26: 81-89, 2011.
20. Liu A, Chen H, Tong H, et al: Emodin potentiates the antitumor effects of gemcitabine in pancreatic cancer cells via inhibition of nuclear factor-kappaB. Mol Med Rep 4: 221-227, 2011.
21. Li J, Liu P, Mao H, Wanga A and Zhang X: Emodin sensitizes paclitaxel-resistant human ovarian cancer cells to paclitaxelinduced apoptosis in vitro. Oncol Rep 21: 1605-1610, 2009.
22. Ko JC, Su YJ, Lin ST, et al: Suppression of ERCC1 and Rad51 expression through ERK1/2 inactivation is essential in emodinmediated cytotoxicity in human non-small cell lung cancer cells. Biochem Pharmacol 79: 655-664, 2010.
23. Chun-Guang W, Jun-Qing Y, Bei-Zhong L, et al: Antitumor activity of emodin against human chronic myelocytic leukemia K562 cell lines in vitro and in vivo. Eur J Pharmacol 627: 33-41, 2010.
24. Chen H, Wei W, Guo Y, et al: Enhanced effect of gemcitabine by emodin against pancreatic cancer in vivo via cytochrome C-regulated apoptosis. Oncol Rep 25: 1253-1261, 2011.
25. Wei WT, Chen H, Ni ZL, et al: Antitumor and apoptosis-promoting properties of emodin, an anthraquinone derivative from Rheum officinale Baill, against pancreatic cancer in mice via inhibition of Akt activation. Int J Oncol 39: 1381-1390, 2011.
26. Wang ZH, Chen H, Guo H C, et al: Enhanced antitumor efficacy by the combination of emodin and gemcitabine against human pancreatic cancer cells via downregulation of the expression of XIAP in vitro and in vivo. Int J Oncol 39: 1123-1131, 2011.
27. Hengartner MO: The biochemistry of apoptosis. Nature 407: 770-776, 2000.
28. Degterev A, Boyce M and Yuan J: A decade of caspases. Oncogene 22: 8543-8567, 2003. (Pubitemid 38028527)
29. Fulda S: Tumor resistance to apoptosis. Int J Cancer 124: 511-515, 2009.
30. Shiozaki EN and Shi Y: Caspases, IAPs and Smac/DIABLO: mechanisms from structural biology. Trends Biochem Sci 29: 486-494, 2004. (Pubitemid 39158872)
31. Wei W-T, Chen H, Wang Z-H, et al: Enhanced anti tumor efficacy of gemcitabine by evodiamine on pancreatic cancer via regulating PI3K/Akt pathway. Int J Biol Sci 8: 1-14, 2012.
32. Neumann M and Naumann M: Beyond IkappaBs: alternative regulation of NF-kappaB activity. FASEB J 21: 2642-2654, 2007. (Pubitemid 47372732)
33. Trauzold A, Roder C, Sipos B, et al: CD95 and TRAF2 promote invasiveness of pancreatic cancer cells. FASEB J 19: 620-622, 2005. (Pubitemid 40471264)
34. Banerjee S, Wang Z, Kong D and Sarkar FH: 3, 3'-Diindolylmethane enhances chemosensitivity of multiple chemotherapeutic agents in pancreatic cancer. Cancer Res 69: 5592-5600, 2009.
35. Lee SH, Ryu JK, Lee KY, et al: Enhanced antitumor effect of combination therapy with gemcitabine and apigenin in pancreatic cancer. Cancer Lett 259: 39-49, 2008. (Pubitemid 350235089)
36. Uwagawa T, Chiao PJ, Gocho T, Hirohara S, Misawa T and Yanaga K: Combination chemotherapy of nafamostat mesilate with gemcitabine for pancreatic cancer targeting NF-kappaB activation. Anticancer Res 29: 3173-3178, 2009.
37. Fahy BN, Schliman MG, Virudachalam S and Bold RJ: Inhibition of AKT abrogates chemotherapy-induced NF-kappaB survival mechanisms: implications for therapy in pancreatic cancer. J Am Coll Surg 198: 591-599, 2004. (Pubitemid 38446534)
38. Kuo TC, Yang JS, Lin MW, et al: Emodin has cytotoxic and protective effects in rat C6 glioma cells: roles of Mdr1a and nuclear factor kappaB in cell survival. J Pharmacol Exp Ther 330: 736-744, 2009.
39. Bhanot U, Heydrich R, Moller P and Hasel C: Survivin expression in pancreatic intraepithelial neoplasia (PanIN): steady increase along the developmental stages of pancreatic ductal adenocarcinoma. Am J Surg Pathol 30: 754-759, 2006. (Pubitemid 44265002)
40. Pennati M, Folini M and Zaffaroni N: Targeting survivin in cancer therapy: fulfilled promises and open questions. Carcinogenesis 28: 1133-1139, 2007. (Pubitemid 47062670)